Clinical Trial Update: Bioequivalence of Two Insulin Aspart Formulations (100 U/mL Versus 200 U/mL) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating bioequivalence between insulin aspart formulations at 100 U/mL and 200 U/mL in diabetes patients and healthy volunteers; the study has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• insulin aspart 100 U/mL (insulin aspart)
• insulin aspart 200 U/mL (insulin aspart)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Diabetes, Healthy | Phase 1 | Status: COMPLETED